anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Bunionette deformity (BD) is a painful condition of the fifth metatarsal characterized by an osseous prominence and fifth toe varus deformity. The purpose of this study is to assess the clinical, functional, and radiographic outcomes of percutaneous distal metatarsal metaphyseal osteotomy (DMMO) without fixation or postoperative strapping of the foot.
METHODS: A retrospective case series was performed on 111 patients (132 feet) with symptomatic BD who underwent percutaneous DMMO of the fifth metatarsal from September 2020 to January 2022 by an experienced minimally invasive surgeon. According to the Shimobayashi classification, we treated 1 type I deformity, 37 type II deformities, 52 type III deformities, 42 feet with type IV deformity, and no patient with a type V deformity. Ninety patients (81%) underwent unilateral osteotomy, and 21 (19%) had bilateral osteotomies. Most cases included other procedures including treatment of 114 associated deformities of the same feet: 68 bunions, 12 lesser metatarsal osteotomies (2-3-4 metatarsals), and 34 hammertoes (20 second hammertoes, 10 third hammertoes, 1 fourth hammertoes, 2 fifth hammertoes). Patient-reported clinical outcome measures, including the Foot Function Index (FFI) questionnaire, the visual analog score (VAS), and overall satisfaction were collected. Fourth-to-fifth intermetatarsal angle (IMA) correction, time to bone union, and complication rates were assessed in all patients.
RESULTS: Mean follow-up was 24.1 months (range, 14-39 months). Both radiographic parameters and patient-reported outcome measures significantly improved after DMMO procedure. The average fourth-to-fifth IMA improved from 12.2 degrees, preoperatively, to 4.4 degrees, postoperatively (P < .001). Patient outcomes reflect the overall outcomes of the combined surgeries on a per-patient basis. Preoperatively, patients had a mean VAS score of 7.6, which improved to 0.6 at the last follow-up (P < .001). Furthermore, the average FFI significantly decreased from pre- to postoperation from 19.2 to 4.4, respectively (P < .001). Overall, 108 of 111 patients reported being satisfied with the outcomes of the procedure. Average bone union was achieved at 12.6 weeks postoperation, with a minimum of 12 and a maximum of 25 weeks. The complication rate was 1.5%, including 1 case of an asymptomatic cock-up deformity and 1 case of lateral fifth metatarsal shaft bone overhang pain, which resolved with an exostectomy.
CONCLUSION: The results of this study of patients who had minimally invasive surgery from an experienced surgeon suggest that percutaneous DMMO of the fifth metatarsal without internal fixation or postoperative immobilization or strapping can be effective at improving radiographic alignment, pain, function, and overall satisfaction with minimal rates of complication.
LEVEL OF EVIDENCE: Level IV, case series.
<P>PROBLEM TO BE SOLVED: To obtain an aroma liquid composition that eliminates problems of clogging and inflammability of a porous container to be used, has excellent palatability and UV stability and exhibits a new color.  <P>SOLUTION: The aroma liquid composition is obtained by adding ≥0.1 wt.% of water to a solution of a glycol ether and/or a glycol acetate having dissolved 25-50 wt.% of an oily perfume and making a homogeneous system. Preferably, the content of water is 1-25 wt.% so as to maintain a homogeneous system. The homogeneous system is made transparent as a whole. When the solution of the glycol ether and/or the glycol acetate is a colored solution, the color and/or the lightness and darkness of the solution is changed by water content and the composition is stable to an ultraviolet light.  <P>COPYRIGHT: (C)2007,JPO&INPIT
FIELD: chemistry. ^ SUBSTANCE: invention relates to a compound which is capable of forming aldehyde- or ketone-type aromatic compounds which ensure prolonged release of an aroma. The compound has formula (I) X-CR1R2R3, where R1 denotes a saturated or unsaturated hydrocarbon group having 6-16 carbon atoms, where said hydrocarbon group can have 0, 1 or more functional groups selected from OH and ether (-O-); R2 denotes H or a saturated or unsaturated hydrocarbon group having 6-16 carbon atoms, where said hydrocarbon group can have 0, 1 or more functional groups selected from OH and ether (-O-); R3 denotes X or OH; X denotes part of a molecule of formula II: ^ ^ or an ammonium or C1-C4 alkylammonium salt of part of a molecule formula II, where x equals 0 or 1; y equals 0 or 1; z equals 0 or 1; m is a number ranging from 2 to 10; n is a number ranging from 0 to 10; o is a number ranging from 0 to 10; R4 denotes H or a C1-C4 alkyl group; R5 denotes a C6-C22 alkyl or alkenyl group or, if n or o is equal to at least 1, a C7-C23 acyl group; R6 denotes H or R5; R7 denotes a C1-C4 alkylene group. The invention also discloses a composition containing, in an aqueous solution, a mixture of at least two compounds of formula I; use of the compound of formula I to slow down release of the aldehyde- or ketone-type aromatic compound from fibre; use of the compound of formula I to increase stability of an aromatic substance for a fabric softener or hair conditioner; hair conditioner containing a compound of formula I; a fabric softener containing a compound of formula I; use of the compound of formula I to improve deposition a fragrance component on fibre; and a method of producing the compound of formula I, which involves reaction of a compound of formula X-H with a compound of formula R1COR2, where R1, R2 and X assume the same values as in the compound of formula I. ^ EFFECT: controlled and stable release of aldehyde- or ketone-type aromatic compounds from substrates on which a compound of formula I was deposited. ^ 18 cl, 1 dwg, 3 tbl, 5 ex
PROBLEM TO BE SOLVED: To obtain a solid cosmetic material capable of maintaining stability of a system after a heat treatment and keeping characteristics such as freshness, nonstickiness, etc., easy to carry, and easy to handles by blending a specific compound in an oil-in-water type solid cosmetic material component. SOLUTION: In an oil-in-water type solid cosmetic material, barium sulfate is blended when blending components or, if needed, when the blended materials are filled in a vehicle. Barium sulfate, which is an essential ingredient, is preferably blended in about 3-20wt.%. As ingredients for the oil-in-water type solid cosmetic material, those containing an amphoteric surfactant (e.g. an amide betain type surfactant, etc.), a higher fatty acid (e.g. caproic acid, etc.) and a wax ester (e.g. stearic acid, etc.) are preferable. The cosmetic material expresses action effect for stable keeping physical characteristics and the excellent action effect is significantly expressed especially in a system containing ionic ingredients using the fatty acid/ammonia and the amphoteric surfactant/the higher fatty acid/the wax ester.
FIELD: medicine, particularly, stomatology. SUBSTANCE: invention deals with treating and prophylactic remedies for care of teeth and oral cavity. Tooth paste contains calcium glycerophosphate, zinc oxide, calcium hydroxide, sodium hydrocarbonate, powder of egg shell, colankhoe juice, aloe extract, sage extract, polyethyleneoxide, glycerine, sorbitol and flavoring. Using of tooth paste reduces dental deposit by 65%, and inflammations in oral cavity by 85.5%. EFFECT: reduced dental deposit and inflammations in oral cavity. 1 cl, 2 tbl
Alternative and less toxic treatments need to be investigated for the treatment of HIV infection. Studies have shown that the dideoxynucleosides ddI and ddC may be effective antiretroviral agents in the treatment of HIV-infected individuals. However, ddI and ddC have yet to be compared on the basis of patient survival, drug tolerance, immunologic and virologic effectiveness, and the incidence of opportunistic infection or opportunistic malignancy. Results of this study will yield information regarding the relative therapeutic benefits and toxicities of each drug while providing alternative treatment to patients who are unable to tolerate or have had progression of disease while on AZT.

After baseline screening, patients are randomized to one of two treatment arms (ddI or ddC). Subjects are evaluated biweekly for the first 4 weeks of study, at 2 months, and every other month thereafter. Three dose levels of ddI (based on patient's weight at study entry) are compared with two dose levels of ddC (also based on patient weight). Patients who reach a new progression-of-disease primary endpoint after at least 12 weeks of treatment or a drug intolerance endpoint have the option of switching over to the alternate study drug; however, participants are encouraged to remain on their original drug assignment whenever possible. For any switchover, patients must be off the originally assigned drug for at least 72 hours before switching. Only one switchover is allowed.
Mastocytosis is a group of pathologies characterized by the accumulation and/or clonal proliferation of abnormal mast cells in various organs. Mastocytosis is a rare disease with an estimated prevalence of between 1/20,000 and 1/40,000. The impact of mastocytosis on health, quality of life, the psychoaffective sphere and on professional life constitutes the burden of this disease. This is probably important but very little studied so far. The DALY is the disability-adjusted life expectancy. It is calculated by subtracting from life expectancy the number of years "lost" due to illness, disability or early death.

Ignorance of the disease and diagnostic error cause significant distress in patients. In our clinical experience, the impact of the disease on the personal, social, and professional life of our patients is major. It therefore seems important to better specify the impact on the quality of life and the costs of this pathology. The main objective of this study is to evaluate the DALY in indolent mastocytosis patients from the CEREMAST reference center of the Toulouse University Hospital.
Patient recruitment will be performed via information dissemination on bulletin boards to advertise the study among patients at the clinics and wards of the First Affiliated Hospital of Dalian Medical University, China. Patients interested in participation in this study or their legal guardians contact the project manager via telephone. Patients will be screened according to the inclusion and exclusion criteria after providing signed informed consent. Eligible patients with chronic spinal cord injury will receive intravenous, lumbar, and local administration of hUC-MSCs/hUCB-MSCs (provided by Cell Bank of Stem Cell Clinical Research Institute, The First Affiliated Hospital of Dalian Medical University). The primary outcome measure of this study is neurologic function scores, including ASIA (American Spinal Injury Association) motor score, ASIA sensory score, ASIA impairment scale (ASIA classification), and acupuncture score. These scores will be used to evaluate the recovery of nerve function after spinal cord injury and determine the therapeutic efficacy and persistence. The secondary outcome measures of this study include Walking Index of Spinal Cord Injury (WISCI), Spinal Cord Independence Measure (SCIM), Kunming Locomotion Scale (KLS), Modified Ashworth Scale (MAS), and Visual Analogous Scale (VAS) scores and the incidence of adverse reactions. At 1, 3, 6 and 12 months after treatment, patients will be followed up to evaluate the efficacy and safety of hUC-MSCs)/hUCB-MSCs transplantation in the treatment of spinal cord injury.
The spike protein of SARS-CoV-2 as well as its receptor binding domain (RBD) has been demonstrated to be capable of activating the release of pro-inflammatory mediators in endothelial cells and immune cells such as monocytes. However, the effects of spike protein or its RBD on airway epithelial cells and mechanisms underlying these effects have not been adequately characterized. Here, we show that the RBD of spike protein alone can induce bronchial epithelial inflammation in a manner of ATP/P2Y2 dependence. Incubation of human bronchial epithelia with RBD induced IL-6 and IL-8 release, which could be inhibited by antibody. The incubation of RBD also up-regulated the expression of inflammatory indicators such as ho-1 and mkp-1. Furthermore, ATP secretion was observed after RBD treatment, P2Y2 receptor knock down by siRNA significantly suppressed the IL-6 and IL-8 release evoked by RBD. Additionally, S-RBD elevated the phosphorylation level of ERK1/2, and the effect that PD98059 can inhibit the pro-inflammatory cytokine release suggested the participation of ERK1/2. These novel findings provide new evidence of SARS-CoV-2 on airway inflammation and introduce purinergic signaling as promising treatment target.
BACKGROUND: The multimorbidity of Atherosclerotic cardiovascular disease (ASCVD) and many other chronic conditions is becoming common. This study aimed to assess multimorbidity distribution in ASCVD among adults in the United States from 1999 to 2018.
METHODS: This cross-sectional survey from the National Health and Nutrition Examination Survey (NHANES) 1999-2018 using stratified multistage probability design. Among the 53,083 survey respondents during the study period, 5,729 US adults aged ≥ 20 years with ASCVD. Joinpoint regression was used to assess the statistical significance of prevalence trends in the prevalence of ASCVD stratified by multimorbidity. The Apriori association rule mining algorithm was used to identify common multimorbidity association patterns in ASCVD patients.
RESULTS: Overall, 5,729 of 53,083 individuals had ASCVD, and the prevalence showed a slow declining trend (biannual percentage change = -0.81%, p = 0.035, average 7.71%). The prevalence of ASCVD significantly decreased in populations without dyslipidemia, diabetes mellitus (DM), hypertension, asthma, chronic obstructive pulmonary disease (COPD), and arthritis (all groups, p < 0.05). Additionally, 65.6% of ASCVD patients had at least four of the 12 selected chronic conditions, with four and five being the most common numbers of conditions (17.9% and 17.7%, respectively). The five most common chronic conditions were (in order) dyslipidemia, hypertension, arthritis, chronic kidney disease, and DM. The coexistence of hypertension and dyslipidemia had the highest support in association rules (support = 0.63), while the coexistence of dyslipidemia, hypertension, metabolic syndrome, and DM had the highest lift (lift = 1.82).
CONCLUSIONS: During the 20-year survey period, there was a significant decrease in the overall prevalence of ASCVD. However, this reduction was primarily observed in individuals without dyslipidemia, DM, hypertension, asthma, COPD, and arthritis. Among populations with any of the evaluated chronic conditions, the prevalence of ASCVD remained unchanged. Most of ASCVD patients had four or more concurrent chronic conditions.
The invention provides a process for improving the stability of a dihydropyridine solid preparation, which comprises the following steps: s1, adding a dihydropyridine organic solvent into the reaction kettle, and stirring to completely dissolve to obtain a dihydropyridine solution. And S2, adding the surfactant into another clean container, and stirring with purified water to dissolve the surfactant to obtain a surfactant solution. S3, crushing the auxiliary materials, and sieving the crushed auxiliary materials with a 60-mesh sieve for later use. S4, placing the crushed and sieved auxiliary materials into a fluidized bed, and controlling the temperature of the materials below 45 ℃ all the time. S5, after the dihydropyridine solution in S1 is spray-dried, the surfactant solution in S2 is replaced for spray drying, and the water content is controlled to be less than 3.0%, so that the dihydropyridine preparation with better stability is obtained. The technical scheme of combining the water-soluble auxiliary material with the surfactant can improve the stability of the dihydropyridine solid preparation and simultaneously improve the current situation of poor water solubility of the dihydropyridine.
The primary purpose of this study is to examine how vulnerabilities in psychological and social situations affect financial quality of life. For people who are experiencing financial hardship, a cancer diagnosis can be devastating. For others, cancer may cause or even worsen financial stress, for example, with their work, their ability to maintain benefits such as health insurance, their ability to pay bills, and their ability to get the cancer treatment they need. The impact of cancer on financial quality of life is an important area of study within cancer care. Considering the financial burden of cancer also lends greater appreciation for the problems that people face if they cannot handle cancer's costs, or if needed resources are either not present or are too stretched to help with the care they need. For this study, up to 180 cancer patients will be interviewed with a written questionnaire. Of this group, 15 people will also be asked if they would like to participate in a follow-up personal interview with the researcher. The major hypothesis of this study is: The greater the vulnerabilities in predisposing factors and enabling factors, the greater the need factors with respect to cancer diagnosis and treatment, and the lower the perceived ability to adhere to treatment, the poorer will be the financial quality of life.
Teratogenic Effects: Pregnancy Category C 

Oral administration of ciclesonide in rats up to 900 mcg/kg/day (approximately 10 times the maximum human daily inhalation dose based on mcg/m2/day) produced no teratogenicity or other fetal effects. However, subcutaneous administration of ciclesonide in rabbits at 5 mcg/kg/day (less than the maximum human daily inhalation dose based on mcg/m2/day) or greater produced fetal toxicity. This included fetal loss, reduced fetal weight, cleft palate, skeletal abnormalities including incomplete ossifications, and skin effects. No toxicity was observed at 1 mcg/kg (less than the maximum human daily inhalation dose based on mcg/m2). 

There are no adequate and well-controlled studies in pregnant women. ALVESCO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Experience with oral corticosteroids since their introduction in pharmacologic as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans. In addition, because there is a natural increase in corticosteroid production during pregnancy, most women will require a lower exogenous corticosteroid dose and many will not need corticosteroid treatment during pregnancy. 

Non-teratogenic Effects: Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully monitored.
PURPOSE: To assess whether performance in attention and executive functions evaluated with the Epitrack screening tool before surgery can differentiate memory and quality of life (QOL) profiles, and detect different post-surgical change patterns in these variables in patients with epilepsy.
METHODS: This is a longitudinal study. Seventy-seven patients with drug-resistant epilepsy (mean age = 37.91) underwent a neuropsychological assessment before and one year after surgery. Epitrack, a screening tool that exclusively evaluates attention and executive functioning, was administered in the pre-surgical assessment, and verbal and visual memory and QOL were assessed before and after surgery.
RESULTS: Patients with impaired Epitrack performance had poorer verbal and visual memory than those with intact Epitrack performance, regardless of the time point (for all, p < 0.0001). They also showed a post-surgical decline in immediate verbal recall (p = 0.04) and discriminability (p = 0.001). Patients with intact Epitrack performance did not exhibit this decline. Epitrack total score significantly contributed to 13 and 11% of the variance of post-surgical changes in immediate verbal recall and discriminability, respectively. Epitrack groups did not differ in QOL profiles or changes, but post-surgical immediate verbal recall improvements were related to post-surgical QOL improvements.
CONCLUSION: Our findings underline the utility of Epitrack screening tool to detect different patterns of verbal and visual memory dysfunction, as well as to predict post-surgical verbal memory decline in patients with drug-resistant epilepsy. Patients with lower pre-surgical Epitrack scores appear to be at increased risk for post-surgical memory decline.
PROBLEM TO BE SOLVED: To provide a new water-insoluble DNA cross-linked product, and to provide a method for using the cross-linked product as an environmental cleaning material. SOLUTION: When the aqueous solution or thin solution film of a water-soluble DNA (for example, a DNA originating from the spermary of salmon) on a support or the thin film of a water-soluble DNA on a support is irradiated with ultraviolet light having wavelengths in the range of 250 to 270 nm, the DNA is changed into the water-insoluble cross-linked product immobilized on the support. Similarly, when the aqueous solution of the water-soluble DNA, for example, impregnated into a cellulose fiber nonwoven fabric is irradiated with the ultraviolet light having wavelengths in the range of 250 to 270 nm, the cellulose fiber nonwoven fabric coated with the water-insoluble cross-linked polymer of the DNA is formed. The cross-linked product can absorb intercalating agents into DNA or endocrine disruptors in an extremely low concentration state in a largely high yield.  The cross-linked product similarly adsorbs toxic metals such as Hg ion in a water-insoluble state. Thereby, the cross-linked product is useful as an environmental cleaning material.
The study design will involve analysis of platelet splicing/activity before and after exposure to a single, 180 mg loading dose of ticagrelor. All subjects will be cardiovascular healthy.